- ongoing, recruitingHuman Pharmacology (Phase I)- First administration to humans
A clinical study of MK-1289 in healthy adult men (MK-1289-001)
This study is looking at a new medicine called MK-1289 in healthy adult men. It's the very first time this medicine is being given to people, and the main goal is to see if it's safe and how the body handles it. It's hoped this medicine might help with COVID-19 someday.
Belgium - ongoing, recruitingTherapeutic use (Phase IV)
COVID-19 vaccine immunological studies in Finland
This study in Finland is looking at how well different COVID-19 vaccines protect people. It's especially interested in how strong our body's defence (antibodies) is six months after two vaccine doses, and how this works against current virus types.
Finland - authorisedTherapeutic use (Phase IV)
Temporal kinetics of antibody and cellular response markers and relative impact of revaccination in patients recovered from COVID-19 after treatment with monoclonal antibodies
This study looks at how well different COVID-19 vaccines work in people who've had COVID and were treated with special antibody medicines. It checks how their immune system responds over time and if getting a booster vaccine at 4 or 12 months makes a difference.
Italy - recruitingPHASE3
A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised
This study looks at new treatments for COVID-19 in adults with weakened immune systems. We want to see if a medicine called ibuzatrelvir, alone or with remdesivir, works better and is safer than remdesivir alone for those who are unwell but not needing oxygen.
United States · Argentina · Belgium